EHC Encompass Health (EHC) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-hospitals · CIK 0000785161
Congress · 1Form 144 · 4
Insider buyers, 180 days
0
Funds added, last quarter
293
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $1.1M priced
What the filings say about EHC
Insiders, 180 days
-$29.5M net sold
5 sellers · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2025-10-31
Planned sales (Form 144), 90 days
$25.8M
4 notices
Encompass Health insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, Encompass Health Corp insiders sold a net $29.5M of stock across 41 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 10, 2026.
- The trade is 6.5% of the 75,041 shares held after it.
- 3 other insiders sold within 30 days.
- 293 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP, Gen Counsel & Secretary Darby John Patrick sold about $588.3K of EHC on Aug 31, 2026; 3 other insiders sold within 30 days and 293 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 13, 2025.
- The trade is 7.5% of the 69,483 shares held after it.
- 3 other insiders sold within 30 days.
- 293 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Price Andrew L sold about $630.2K of EHC on Aug 31, 2026; 3 other insiders sold within 30 days and 293 funds added in the latest 13F quarter.Context
- 9 earlier Form 4 trades (code P or S) here by this insider (9 sales), the last on May 15, 2026.
- The trade is 37.4% of the 50,508 shares held after it.
- 3 other insiders sold within 30 days.
- 293 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: EVP & Chief Financial Officer COLTHARP DOUGLAS E sold about $2.4M of EHC on Aug 10, 2026; 3 other insiders sold within 30 days and 293 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Feb 11, 2026.
- The trade is 63.7% of the 269,393 shares held after it.
- 3 other insiders sold within 30 days.
- 293 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Tarr Mark J sold about $21.5M of EHC on Aug 10, 2026, the largest insider sale at the company on our record; 3 other insiders sold within 30 days and 293 funds added in the latest 13F quarter.Context
- 12 earlier Form 4 trades (code P or S) here by this insider (12 sales), the last on Feb 11, 2026.
- The trade is 0.6% of the 267,814 shares held after it.
- 3 other insiders sold within 30 days.
- 293 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President & CEO Tarr Mark J sold about $199.0K of EHC on Aug 10, 2026; 3 other insiders sold within 30 days and 293 funds added in the latest 13F quarter.41 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$29.5M over 180 days
-$26.4M over 90 days
below 81% of Healthcare Services
Congress
1 member bought in the last year
the lowest in Healthcare Services
Funds
293 funds bought in last quarter
more than 86% of Healthcare Services
Revenue
+10.5% year over year
below 52% of Healthcare Services
Margin
9.5% net margin
more than 90% of Healthcare Services
Buybacks
$145.8M repurchased, FY to 2026-06-30
more than 71% of Healthcare Services
Short interest
3.6% of the float short (float per yahoo 2026-10-26) · 3.5 days to cover · settled 2026-09-30
more than 53% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch EHC
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-1.3%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns EHC: institutional holders (13F)
13F holdings, latest reported quarter
10,484,385 sh
$1.1B
4,924,664 sh
$497.8M
4,475,896 sh
$452.4M
3,278,739 sh
$331.4M
3,185,798 sh
$322.0M
Congress trades in EHC
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2025-10-31 · disclosed 21 days later
$1,001 - $15,000
Bought 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Sold 2025-10-30 · disclosed 22 days later
$1,001 - $15,000
Bought 2025-07-22 · disclosed 22 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
EHC planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
John Patrick Darby
Filed 2026-08-31
$588.3K
Douglas Coltharp
Filed 2026-08-10
$2.4M
John Patrick Darby
Filed 2026-08-10
$1.1M
Mark Tarr
Filed 2026-08-10
$21.7M
EHC mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Madison Small Cap Fund
$7.0M position · as of 2026-07-31
4.5%
Jensen Quality Mid Cap Fund
$4.1M position · as of 2026-05-31
4.3%
CapForce IBD Breakout Opportunities ETF
$636.0K position · as of 2026-07-31
3.9%
ICON HEALTH AND INFORMATION TECHNOLOGY FUND
$3.6M position · as of 2026-06-30
3.7%
TimesSquare Quality Mid Cap Growth ETF
$1.5M position · as of 2026-05-31
3.3%
Reinhart Mid Cap PMV Fund
$2.4M position · as of 2026-05-31
2.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Encompass Health Corporation Political Action Committee
Cycle 2026 · $131K spent
$146.5K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Mr. Tarr
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$10.3M
$20.6M
$2.9M
+70%
+13%
2024
$9.3M
$17.9M
$2.2M
+47%
-5%
2023
$8.8M
$14.1M
$2.8M
+6%
-7%
2022
$7.7M
$9.9M
$1.9M
-6%
-12%
2021
$8.3M
$6.2M
$2.3M
-20%
+10%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $29.5M sold by insiders over 180 days, 293 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $25.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
EHC financials
Revenue growth
+10.5%
XBRL, annual
Net margin
9.5%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$6.2B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM EHC
| FY Dec 2025 | $5.9B |
| FY Dec 2024 | $5.4B |
| FY Dec 2023 | $4.8B |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | $1.6B |
| Mar 2026 | $1.6B |
| Dec 2025 | $1.5B |
| Sep 2025 | $1.5B |
| Jun 2025 | $1.5B |
| Mar 2025 | $1.5B |
| Dec 2024 | $1.4B |
| Sep 2024 | $1.4B |
At each fiscal year end
Single quarter
Net margin, TTM
+10.0%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM EHC
| FY Dec 2025 | +9.5% |
| FY Dec 2024 | +8.5% |
| FY Dec 2023 | +7.3% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | +9.6% |
| Mar 2026 | +12.3% |
| Dec 2025 | +9.5% |
| Sep 2025 | +8.6% |
| Jun 2025 | +9.7% |
| Mar 2025 | +10.4% |
| Dec 2024 | +8.6% |
| Sep 2024 | +8.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$122.2M
operating cash flow minus capex, 2022-07-01 to 2023-06-30
Free cash flow, TTM EHC
| FY Dec 2025 | -$59.5M |
| FY Dec 2024 | $34.4M |
| FY Dec 2023 | $93.8M |
| FY Dec 2022 | $141.0M |
| FY Dec 2021 | $191.2M |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Debt to equity
1.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Debt to equity EHC
| FY Dec 2025 | 1.00x |
| FY Dec 2024 | 1.14x |
| FY Dec 2023 | 1.63x |
| FY Dec 2022 | 2.09x |
| FY Dec 2021 | 1.70x |
| Jun 2026 | 1.00x |
| Mar 2026 | 1.00x |
| Dec 2025 | 1.00x |
| Sep 2025 | 1.01x |
| Jun 2025 | 1.02x |
| Mar 2025 | 1.08x |
| Dec 2024 | 1.14x |
| Sep 2024 | 1.20x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.26x
TTM operating cash flow over long-term debt only, 2026-06-30
Cash flow to debt EHC
| FY Dec 2025 | 0.28x |
| FY Dec 2024 | 0.29x |
| FY Dec 2023 | 0.25x |
| FY Dec 2022 | 0.26x |
| FY Dec 2021 | 0.22x |
| Jun 2026 | 0.26x |
| Mar 2026 | 0.27x |
| Dec 2025 | 0.28x |
| Sep 2025 | 0.28x |
| Jun 2025 | 0.29x |
| Mar 2025 | 0.29x |
| Dec 2024 | 0.29x |
| Sep 2024 | 0.29x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+25.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity EHC
| FY Dec 2025 | +25.1% |
| FY Dec 2024 | +24.5% |
| FY Dec 2023 | +23.8% |
| FY Dec 2022 | +16.8% |
| FY Dec 2021 | +23.6% |
| Jun 2026 | +25.5% |
| Mar 2026 | +26.0% |
| Dec 2025 | +25.1% |
| Sep 2025 | +25.0% |
| Jun 2025 | +25.4% |
| Mar 2025 | +25.4% |
| Dec 2024 | +24.5% |
| Sep 2024 | +24.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+8.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets EHC
| FY Dec 2025 | +8.3% |
| FY Dec 2024 | +7.2% |
| FY Dec 2023 | +6.0% |
| FY Dec 2022 | +4.3% |
| FY Dec 2021 | +6.2% |
| Jun 2026 | +8.7% |
| Mar 2026 | +8.7% |
| Dec 2025 | +8.3% |
| Sep 2025 | +8.1% |
| Jun 2025 | +7.9% |
| Mar 2025 | +7.7% |
| Dec 2024 | +7.2% |
| Sep 2024 | +6.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+8.7%
operating income after a 20.5% effective tax rate, over long-term debt only, 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital EHC
| FY Dec 2025 | +9.3% |
| FY Dec 2024 | +10.4% |
| FY Dec 2023 | +10.2% |
| FY Dec 2022 | +9.7% |
| FY Dec 2021 | n/a |
| Jun 2026 | +8.7% |
| Mar 2026 | +9.0% |
| Dec 2025 | +9.3% |
| Sep 2025 | +9.7% |
| Jun 2025 | +10.2% |
| Mar 2025 | +10.5% |
| Dec 2024 | +10.4% |
| Sep 2024 | +10.7% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+8.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed EHC
| FY Dec 2025 | +9.0% |
| FY Dec 2024 | +9.7% |
| FY Dec 2023 | +10.3% |
| FY Dec 2022 | +9.7% |
| FY Dec 2021 | +9.4% |
| Jun 2026 | +8.6% |
| Mar 2026 | +8.8% |
| Dec 2025 | +9.0% |
| Sep 2025 | +9.3% |
| Jun 2025 | +9.3% |
| Mar 2025 | +9.5% |
| Dec 2024 | +9.7% |
| Sep 2024 | +9.9% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
20.21x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing EHC
| FY Dec 2025 | 19.16x |
| FY Dec 2024 | 20.71x |
| FY Dec 2023 | 19.28x |
| FY Dec 2022 | 22.15x |
| FY Dec 2021 | 12.63x |
| Jun 2026 | 16.46x |
| Mar 2026 | 16.15x |
| Dec 2025 | 19.16x |
| Sep 2025 | 24.01x |
| Jun 2025 | 24.00x |
| Mar 2025 | 20.93x |
| Dec 2024 | 20.71x |
| Sep 2024 | 23.40x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$14.7B
market value at close 2026-10-26 on 2026-07-28 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
Enterprise value EHC
| FY Dec 2025 | $13.1B |
| FY Dec 2024 | $11.6B |
| FY Dec 2023 | $9.3B |
| FY Dec 2022 | $8.7B |
| FY Dec 2021 | $8.4B |
| Jun 2026 | $12.5B |
| Mar 2026 | $12.0B |
| Dec 2025 | $13.1B |
| Sep 2025 | $15.1B |
| Jun 2025 | $14.6B |
| Mar 2025 | $12.4B |
| Dec 2024 | $11.6B |
| Sep 2024 | $11.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-1.0%
TTM free cash flow over market value at close 2026-10-26
FCF yield EHC
| FY Dec 2025 | -0.6% |
| FY Dec 2024 | +0.4% |
| FY Dec 2023 | +1.4% |
| FY Dec 2022 | +2.4% |
| FY Dec 2021 | +3.7% |
| Jun 2026 | -1.2% |
| Mar 2026 | -0.6% |
| Dec 2025 | -0.6% |
| Sep 2025 | -0.2% |
| Jun 2025 | +0.1% |
| Mar 2025 | +0.1% |
| Dec 2024 | +0.4% |
| Sep 2024 | +0.1% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
1.00x
P/E over trailing EPS growth of 20%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing EHC
| FY Dec 2025 | 0.79x |
| FY Dec 2024 | 0.72x |
| FY Dec 2023 | 0.69x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.29x |
| Jun 2026 | 0.82x |
| Mar 2026 | 0.68x |
| Dec 2025 | 0.79x |
| Sep 2025 | 0.85x |
| Jun 2025 | 0.78x |
| Mar 2025 | 0.67x |
| Dec 2024 | 0.72x |
| Sep 2024 | 1.30x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $5.9B | $5.4B | $4.8B | $4.3B |
| Operating income | n/a | n/a | n/a | $539.5M |
| Net income | $566.2M | $455.7M | $352.0M | $271.0M |
| EPS (diluted) | 5.54 | 4.46 | 3.47 | 2.70 |
| Operating cash flow | n/a | n/a | n/a | $705.8M |
| Cash | $72.2M | $85.4M | $69.1M | $21.8M |
| Long-term debt | $2.4B | $2.4B | $2.7B | $2.7B |
| Buybacks | $158.0M | $31.1M | $0 | $0 |
| Dividends paid | $71.1M | $62.8M | $60.4M | $99.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
EHC Stock Sonar score 6/7 axes
Find similar shapesCompareEHC ranks highest on profitability (68th percentile) and risk and compliance (65th), and lowest on insider conviction (9th), among Healthcare Services peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
EHC filings, in plain words
Are Encompass Health insiders buying or selling EHC?
In the 180 days to 2026-10-28, Encompass Health insiders were net sellers, a net $29.5M across purchases and sales reported on Form 4, by 5 sellers.
Have members of Congress traded EHC?
Yes. In the year to 2026-10-28, 1 House member disclosed buying EHC and 1 House member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31.
Are there planned insider sales of EHC?
Yes. 4 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $25.8M of stock; the latest, by John Patrick Darby, was filed 2026-08-31.
Read the full summary
In the 180 days to 2026-10-28, Encompass Health insiders were net sellers of EHC, a net $29.5M across purchases and sales reported on Form 4 by 5 sellers. None of the 9 insider sales was flagged as made under a Rule 10b5-1 plan. In the year to 2026-10-28, 1 member of Congress disclosed buying EHC and 1 member disclosed selling it; the latest on record is a sale by Lisa McClain dated 2025-10-31. Insiders filed 4 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $25.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
